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ABSTRACT  
Cardiovascular diseases remain the greatest cause of death in the US and gene therapy has the potential to be an effective 
therapy.  In this study, we demonstrated MMP-9 based protease-activatable virus (PAV) for selective infection of 
myocardial infarct (MI) that is associated with active MMP-9 expression.  To test the specificity of PAV, we used 
expression of a far-red fluorescence protein (iRFP) delivered by the PAV together with a dual PET/NIRF imaging agent 
specific for active MMP-9 activity at the site of MI in a murine model. Calibrated fluorescence imaging employed a 
highly-sensitive intensified camera, laser diode excitation sources, and filtration schemes based upon the spectra of iRFP 
and the NIRF agent.  One to two days after ligation of the left anterior descending artery, the PAV or WT AAV9 virus 
encoding for iRFP (5x1010 genomic particles) and radiolabeled MMP-9 imaging agent (3 nmol) were injected 
intravenously (i.v.).  PET imaging showed MMP activity was associated with adverse tissue remodeling at the site of the 
MI.   One week after, animals were again injected i.v. with the MMP-9 agent (3 nmol) and 18-24 h later, the animals 
were euthanized and the hearts were harvested, sliced, and imaged for congruent iRFP transgene expression and NIRF 
signals associated with MMP-9 tissue activity.  The fluorescent margins of iRFP and NIRF contrasted tissues were 
quantified in terms Standard International units of mW/cm2/sr.  The sensitivity, specificity, and accuracy of PAV and 
WT targeting to sites of MI was determined from these calibrated fluorescence measurements.  The PAV demonstrated 
significantly higher delivery performance than that of the WT AAV9 virus.  
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1. INTRODUCTION 
Heart disease is the leading cause of death in the U.S. and close to 5 million Americans have heart failure [1]. Gene 
therapy has the potential to treat a number of cardiac diseases [2-3], with >150 gene therapy clinical trials worldwide for 
cardiovascular indications (J Gene Med database). Promisingly, there are a number of genes that could be delivered to 
treat post-myocardial infarction [4-6].   Unfortunately, many genes would have serious negative side effects if delivered 
systemically.  Many promising therapeutic genes would only be clinically viable if they are delivered in a highly targeted 
manner to diseased cardiac tissues. Currently, specificity for target cardiac tissues is normally attempted through direct 
intramyocardial injection into a previously identified disease location or through the use of catheters to achieve localized 
delivery [7]. To decrease the invasiveness of current gene therapy approaches, delivery vectors need to be better targeted 
to cardiac tissues, enabling vectors to be injected intravenously (i.v.). Such an advancement should lead to the clinical 
translation of a greater number of gene/RNAi therapies for heart disease treatment. 
 
The Suh lab at the Department of Biomedical Engineering at Rice University were the first to create adeno-associated 
virus (AAV) vectors that could be activated by extracellular proteases [8] that are biomarkers of tissue remodeling. 
Matrix metalloproteases -2 and -9 (MMP -2/-9) are gelatinases that are associated with adverse cardiac remodeling after 
myocardial infarct.  The protease-activatable viral (PAV) vector is noninfectious in the absence of proteases but is then 
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able to “switch on” its cell surface receptor binding and cellular transduction behaviors upon exposure to specific 
MMPs. The PAV sensitivity and specificity can be tuned by modifying the amino acid sequence of the ‘peptide lock’ 
that we genetically incorporate into the capsid to build the vector.  
 
Validation of in vivo AAV targeting and infection strategy depends upon quantitatively associating MMP activity with 
vector delivery and transgene expression. Use of far-red fluorescent protein (iRFP) represents a method to assess 
transgene expression in preclinical studies. While molecular imaging of MMP could provide an important companion 
diagnostic in clinical gene therapy trials that employ MMP targeted therapies, fluorescence-based techniques are not 
suited for the deep location of the heart in humans.  Previously, we developed a dual-labeled imaging agent targeting 
active gelatinases (MMP -2/-9) for non-invasive, in vivo microPET/CT and NIRF imaging [9-10].  Herein, we use in 
vivo microPET/CT imaging of mice with induced myocardial infarct to detect MMP activity and ex vivo iRFP and NIRF 
fluorescence measurements calibrated in Standard International (SI) units for assessing accuracy of PAV targeting.   
 
 
2. MATERIALS AND METHODS 
2.1 AAV9-based PAV activated by MMPs and animal model of myocardial infract From a panel of MMP-
activatable AAV9 vectors, one variant, L001 was selected with L001 having superior in vitro reactivity to both MMP-2 
and MMP-9.  To create a myocardial infarct, the left anterior descending artery (LAD) was ligated according to 
published procedures [11]. Two days after induction of the myocardial infarct, WT AAV9, L001 (5x1010 genomic 
particles) were injected i.v. in 0.1 cc.  One week later, the animals were anesthetized with isoflurane, administered 200 
uCi of 18-FDG in 0.1 cc i.v., for microPET imaging 2 hours later to visualize the infarct.  The following day, 200 uCi of 
64-Cu-DOTA-IRDye800-MMP agent was administered in 0.1 cc i.v. for visualizing MMP activity in the infarct.  Two 
weeks after PAV or AAV9 administration, animals were euthanized and the heart tissues collected for fluorescence 
imaging of iRFP transgene expression and NIRF-MMP activity.   
 
2.2 MicroPET/CT Imaging  
Animals were placed on a temperature-controlled pad at 37°C under isoflurane anesthesia.  70% isopropanol was used to 
clean the area at the site of injection (tail vein).  Then an imaging agent was administered (i.v., <200 μL) before imaging.  
18-F gated imaging was conducted immediately while 64-Cu non-gated imaging commenced more than 1 hour after 
agent administration.  Imaging lasted no more than 45 minutes depending upon tissue activity and animals remained 
under isoflurane anesthesia during this time.  Animals were allowed to recover and returned to the animal facility or at 
the last imaging session animals were euthanized and tissues collected.   
 
2.3 iRFP and NIRF Imaging Instrumentation 
Figure 1 provides the schematic of our fluorescence imaging system.   A military-grade NIR sensitive Gen III image 
intensifier was employed to amplify the collected far red and NIRF light and convert it to a phosphor signal for 
registration in the optical green wavelengths by a frame-transfer 16-bit CCD camera.  For iRFP imaging, an optically 
filtered diffused and broadened 690 nm laser diode was used to illuminate tissue surfaces with an incident power of 
around 1.0 mW/cm2.  iRFP fluorescent signals emanating from the animal were collected with two 720 nm band pass 
filters to increase the optical density at the excitation wavelength and reduce the excitation light leakage and improve 
sensitivity.  For NIRF imaging, which has been previously described [12], we employed a 785 nm laser diode filtered 
with a “clean up” filter  with an incident power of around 2.0 mW/cm2.  The collection of fluorescence signals was 
implemented by using two 830 nm band pass filters.    
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2.5 iRFP and NIRF Fluorescence Imaging  
After 9 days post injection of PAV or WT AAV9, mice were sacrificed for in situ iRFP and NIRF fluorescence imaging. 
Then, the organs including hearts, brain, lung, liver, spleen and kidney were harvested for ex vivo both iRFP and NIRF 
fluorescence imaging. Finally, both iRFP and NIRF fluorescence imaging were performed on sliced hearts.  During both 
iRFP and NIRF fluorescence imaging, the integrating time of CCD camera was set to 200 ms and the collected 
fluorescence signals were amplified by adjusting the gain of intensifier, but not exceeding the dynamic range of CCD 
camera (216).  After both iRFP and NIRF fluorescence imaging, the sliced hearts were preserved in 10% formalin for 
pathological examination.   
 
2.6 ROC Analysis for Assessing Tumor Margins from iRFP 
A phantom with SI units of radiance was used to quantify the margin of iRFP contrasted tissues.  NIRF images were 
thresholded to display intensities that were at least 1.86 times greater than that from negative tissues within the same 
field of view (FOV) and the margins were similarly extracted.  The value of 1.86 was chosen as the minimum image 
contrast used for visual identification [13].  The boundary margin areas determined from iRFP and NIRF images were 
then calculated using ImageJ built-in functions.  To assess the performance of the virus, we first compared the sensitivity 
of WT and PAV transfection in MMP denoted tissues.  Sensitivity is defined as = area(MMP+/iRFP+)/(sum of areas 
(MMP+/IRFP+), (MMP+/IRFP-)). Next, we compared the specificity, i.e. how well WT and PAV targeted MMP+ 
tissues (or infarcted tissues).  Specificity is defined as area (IRFP-/MMP-)/(sum of areas (IRFP-/MMP-), (IRFP+/MMP-
). Next we assessed the accuracy of WT versus PAV for targeting only MMP+ tissues (or infarcted tissues).  Accuracy is 
defined as (sum of areas (IRP+/MMP+),(IRP-/MMP-))/(sum of areas (IRFP+/MMP+),(IRFP+/MMP-), (IRFP-
/MMP+),(IRFP-/MMP-)).  The statistical analysis was performed using the paired or unpaired Student’s t-test, and 
Microsoft Office Excel 2010 software.     
 
3. RESULTS 
Figure 2(a) shows an example of the axial and coronal views of an 18-FGD gated PET/CT image with red arrows 
denoting non-viable, left ventricle heart tissues 2 weeks after LAD ligation.  Figure 2(b) illustrates the infarcted heart 6 h 
after administration of 200 uCi of 64Cu-DOTA-IRDye800-MMP showing non-viable tissue uptake.  In the nonviable 
tissue, a constant value of 2% of the injected dose/g (ID/gm) was found at 2, 6, and 24 h after administration. Note the 
MMP agent accumulates in the non-viable region in which there is no 18-FDG uptake. 
 
 
 
 
 
 
Fig.1. A schematic of the ICCD-based NIRF imaging system operating at two different wavelengths. 
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To validate the fluorescence methodology for assessing iRFP transgene expression, WT AAV9 carrying iRFP was 
administered in normal healthy animals with expected non-specific uptake in the heart and in the liver.  As shown in 
Figure 3, 2 and 3 weeks after AAV9 administration, the iRFP expression in the liver and heart could be detected above 
autofluorescence levels in situ, and expression was easily detected ex vivo using the iRFP imaging system. We also 
validated iRFP mRNA expression using qPCR (not shown for brevity) If the PAV is effective, they should show 
decreased iRFP transgene expression in the normal healthy animals and only in the hearts of animals with myocardial 
infarcts.  
 
 
 
Fig.3. In situ and ex vivo iRFP fluorescence images reveal the PAV delivery of iRFP associated with the MMPs in the infarcted 
heart. 
Fig.2. An infarcted heart contrasted by (a) FDG and (b) [64] Cu-DOTA-IRDye 800-MMP imaging agent.  FDG images 
were acquired using gating on EKG. 
(a) 
(b) 
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Figure 4 shows the extracted margins of the typical ex vivo iRFP, and NIRF images of an infarcted, sliced heart. The 
calculated sensitivity, specificity and accuracy are shown in Figure 5.  As expected, L001 and WT AAV9 show equally 
high sensitivity since AAV9 tends to accumulate throughout the heart, but L001 is superior in specificity to infarcted 
tissues than WT AAV9, further evidence of the PAV mode of transduction in vivo. There is no statistical difference 
between L001 and WT AAV9 in sensitivity.  There is a statistical difference between L001 and WT AAV9 in specificity 
and accuracy.    
 
Fig.4. The margins of a representative sliced heart determined by boundary analyses of iRFP, NIRF signals, and their 
overlays. The margins denoted by the iRFP threshold found by phantom and by NIRF contrast of 1.86 are denoted on the 
image. 
Fig.5. The sensitivity, specificity and accuracy of PAV and WT targeting to sites of MI, demonstrating significantly higher 
delivery performance of PAV compared to WT AAV9 virus.  
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4. SUMMARY 
Vectors with specificity to damaged heart tissues would be an advancement towards achieving effective cardiac gene 
therapies.  In this study, PAV was designed to be activated by MMP-9, a tissue marker of myocardial infarction. To test 
the delivery performance of PAV, iRFP far-red fluorescence protein (iRFP) transgene expression was correlated to 
MMP-9 activity as measured with a dual labeled, PET and NIRF labeled targeted peptide.  The results show that the 
accuracy for targeting infarcted tissues is 78% compared to the 6% accuracy of that of WT AAV9 virus (78% vs 6 %). 
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